ABC
GENERAL COMMENTS : SURVEY OF xxxxx, 2007
1] The findings of this visit were reviewed with xxxxi prior to our exit
2] NEXT REVIEW xxxxxxxxxxxx
, 2007
3] We have reviewed occurrences at ABC for the quarter and made
recommendations where appropriate
For the past quarter, there were no medication-related occurrences
requiring our review at ABC
4] Biennial Controlled Drug Inventory IMPORTANT
As we have reviewed, this is a reminder that the federally
required Biennial Controlled Drug Inventory is due on or about
May 1, 2007. I have provided ABC
with the forms and instructions.
Do not mail the forms to me or the
State or Federal Agencies. Maintain
them in an ongoing file:
“BIENNIAL CONTROLLED DRUG INVENTORY”
REMEMBER!...Include OR drugs, PACU,
Anesthesia, Safe…..virtually all drugs in the facility. Best at end of
day. Flag your calendars for the May 1 date
1
5] IV PUSH GUIDELINES
Per our discussion last quarter, it is important that two elements
be in place regarding IV push process at ABC
I again encourage the authorization at ABC
as to which drugs can be pushed by the nursing staff. This should
occur at the medical staff meeting level.
Secondly, I have researched a guideline resource and am
presenting it for staff reference at today’s exit
6] FINANCIAL BENCHMARKS . .
COST CONTAINMENT OPPORTUNISTS
At least once a year, at this time, we will be discussing your
relative costs of high volume drugs at ABC
Going forward, a part of our benchmarking section of our report
will be a comparison that relates to drug acquisition costs as well
as relative size of facility and GPO status.
Q: “ Does ABC
monitor its costs of pharmaceuticals?”
A: “Yes, invoice to invoice and against approximately 90 other
facilities doing our type of work “
See next page
2
OUR 2007 FISCAL INITIATIVE….
SHELDON S. SONES AND ASSOCIATES© BENCHMARKING of COSTS OF KEY DRUGS 2007 1 Q SURVEY
FACILITY/TYPE
APPROX#
PROCEDRES
ANNUALLY
GPO
MEMBERSHIP
MIDAZOLAM
2 ML EACH
5000
2500
YES
YES
1.12
X
MIDAZOLAM 10
ML
EACH
FENTANYL
100MCG/2 ML.
EACH
ONDENSETRON
4 MGEACH
PROPOFOL
20 MG
PROPOFOL
50 MG.
11.15
X
28.00
X
A (Multi)
B (Multi)
C (Multi)
D (Multi)
R(Multi)
U (Multi)
Z (Multi)
M-9 (Multi)
E-3 (Endo)
BB Endo)
DD(Endo)
LV (Endo)
T (Opthal)
CM (Opth)
EB (Opth)
O-13
P (Ortho)
RH(Ortho)
LH (ortho)
X
X
0.34
0.79 (SYR)
X
X
© Sheldon S. Sones and Associates, 2007
7] TEXT REFERENCES
Best practice is to maintain a library of current drug references
for the medical and nursing staffs. Nursing Drugs Handbooks
and PDRs have all been acceptable but we generally
recommend that the reference be current within one year.
Today, best practice would be to assure that new drug
information (which is not included in most stored references) be
accessible.
We recommend that the drug reference process be focused on
internet access and the staff be made aware that this is the key
reference for new drugs
3
8] CONTINUING COMPETENCE –
MEDICATION ADMINISTRATION
We will provide our 2007 Edition of MMCS – ASC
MMCS-ASC
2007 EDITION
MEDICATION MANAGEMENT
COMPETENCY SCREEN
FOR
AMBULATORY SURGICAL CENTERS
SHELDON S. SONES AND ASSOCIATES
© 2007
THE SAFE MANAGEMENT OF DRUG THERAPIES IS AN IMPORTANT
ELEMENT OF ACHIEVING FAVORABLE OUTCOMES IN AMBULATORY
SURGICAL SERVICES. THIS COMPETENCY SCREEN IS NOT MEANT
AS A DEFINITIVE ASSESSMENT OF THE PARTICIPANT. RATHER, IT
IS INTENDED TO SERVE AS A SCREEN FOR MINIMUM SAFE DRUG
MANAGEMENT ELEMENTS FOR MEDICATION ADMINISTRATORS IN
AMBULATORY SURGICAL SERVICES.
© SHELDON S. SONES AND ASSOCIATES
PHARMACY CONSULTANTS TO AMBULATORY SURGICAL CENTERS
15 COACHMEN LANE
NEWINGTON, CONNECTICUT 06111
(860) 604 0014
4
9] We have reviewed the current POINTS
OF EMPHASIS
(Medication and Non-Medication Related) on exit. These reflect recent
survey recommendations by accrediting or State agencies










Reconciliation
Ammonia Inhalants
Ceiling tiles
Fire and Emergency Preparedness for all employees
annually
Door stops
AAAHC = 9W
Policy on assessing acute pain in PACU
Pain and anti N/V outcomes in PACU
Pain assessment on admission/discharge
Alcohol-containing products in the OR
5